Engineered immune cells take on advanced stomach cancer in new trial
NCT ID NCT07538856
First seen Apr 26, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This early-phase trial is testing a new treatment called CT0494BCP for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy uses specially engineered immune cells (CAR-T cells) designed to attack the cancer. The main goals are to check the treatment's safety and find the right dose, while also looking for early signs that it might shrink tumors. About 50 adults aged 18 to 70 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BeijingGoBroadH
Beijing, Beijing Municipality, 10000, China
Conditions
Explore the condition pages connected to this study.